Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study

Sánchez, Luis A.; Pérez, M. A.; Centeno, Indira; M, David; Kahi, D.; Gutierrez, Elizabeth

doi:10.1016/j.fertnstert.2006.07.1507

Cited by 11 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Androgen analysis in eight women with PCOS who underwent 12 weeks of use of the COC containing 30 μg EE/3 mg drospirenone confirmed the reduction in serum androgens and the elevation in SHBG compared with the basal levels. However, after 8 weeks without the use of this COC, the laboratory values of the patients returned to the levels present before use (41), showing that the causative factor of hyperandrogenism was maintained, being only temporarily controlled by the COC.…”

Section: Oral Contraceptives and Hyperandrogenismmentioning

confidence: 89%

Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome

Soares

Vieira

Martins

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

Chronic anovulation, polycystic ovarian morphology and hyperandrogenism are the diagnostic criteria for polycystic ovary syndrome (PCOS). Metabolic disturbances are more common in PCOS women who are prone to develop metabolic syndrome and to present higher levels of some cardiovascular disease risk marker. Oral contraceptives are widely used in PCOS, but conflicting data have been reported regarding their impact on carbohydrate and lipid metabolism on PCOS women. This paper presents a critical evaluation of combined oral contraceptives (COCs) metabolic effect - carbohydrate metabolism and insulin sensitivity, lipid metabolism, haemostasis, body weight, arterial pressure and cardiovascular impact - on PCOS women. Because of the paucity of data on the impact of COCs on cardiovascular and metabolic parameters in PCOS patients, most of there commendations are based on studies involving ovulatory women. The use of low-dose COCs is preferable in PCOS, especially among patients with glucose intolerance, insulin resistance and uncomplicated diabetes mellitus. Although reported as a side effect of COCs, marked weight gain has not been confirmed among users. However, when arterial hypertension or elevated risk for thromboembolism is present, progestogen-only hormonal contraceptives should be used instead of COCs. Regarding dyslipidaemia, COCs reduce low-density lipoprotein and total cholesterol and elevate high-density lipoprotein and triglycerides, and therefore are not recommended for women with high triglycerides levels. The choice of a COC, which alleviates the PCOS-induced hyperandrogenism without significant negative impact on cardiovascular risk, is one of the greatest challenges faced by gynaecologists nowadays.

show abstract

Section: Oral Contraceptives and Hyperandrogenismmentioning

confidence: 89%

Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome

Soares

Vieira

Martins

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Since studies found increased risk of VTE with CHC [66]; but did not find increased odds of VTE with POP, implants or LNG IUS [67], it is acceptable to counsel users of CHC with any VTE risk factor to switch to POP, implants, copper IUD or LNG IUS (if possible) in order to reduce the woman's risk of VTE during a COVID-19 hospitalization, due to thromboinflammation and COVID-19associated coagulopathy [60]. However, this needs to be weighed against the fact that discontinuation of oral CHC requires at least 2 months to restore coagulation parameters [65]; this is also inferred by the return of sex hormone-binding globulin (SHBG) levels to basal values after 8 weeks [68] since SHBG might serve as a surrogate marker for the risk of VTE [69]. Moreover, although CHC slightly increases the risk of VTE, it offers significant protection against pregnancy, a condition associated with a substantially higher risk of VTE [32].…”

Section: Covid-19 Venous Thromboembolism and Hormonal Contraceptionmentioning

confidence: 99%

Contraception and reproductive planning during the COVID-19 pandemic

Filho

Melo

Sorpreso

et al. 2020

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Introduction:The coronavirus disease (COVID-19) is a global health emergency. Major disruption to healthcare services during the current COVID-19 pandemic will last even after its peak. Sexual and reproductive health (SRH), specially contraception, needs to be understood as an essential service. Areas covered: This paper is a narrative review. Data from PubMed/MEDLINE, Scopus, and websites of scientific societies were screened during the months of April and May 2020. It addresses the main aspects related to contraception during the COVID-19 pandemic, with special emphasis on family planning services, extended use of long-acting reversible contraceptive (LARC) methods, drug interactions, and thromboembolism risk. We also specified some issues focused on the Brazilian reality. Expert opinion: Ensuring proper contraception use in the COVID-19 time is very important. We encourage women, healthcare providers, policymakers, and the society to consider SRH services as priority.

show abstract

“…Depending on the results, further investigations may be needed and an interdisciplinary approach involving gynecologists, endocrinologists, and dermatologists may be required. Note that androgen levels testing should be done during the follicular phase, between the fourth and the seventh day of the cycle and that oral contraceptives should be discontinued for at least two months prior to this testing [63]. The patients should be informed that cessation of contraception may induce a three-month lasting telogen effluvium.…”

Section: Other Diagnostic Techniquesmentioning

confidence: 99%

The Female Pattern Hair Loss: Review of Etiopathogenesis and Diagnosis

Vujovic

Marmol

2014

BioMed Research International

View full text Add to dashboard Cite

Female pattern hair loss (FPHL) is the most common hair loss disorder in women. Initial signs may develop during teenage years leading to a progressive hair loss with a characteristic pattern distribution. The condition is characterized by progressive replacement of terminal hair follicles over the frontal and vertex regions by miniaturized follicles, that leads progressively to a visible reduction in hair density. Women diagnosed with FPHL may undergo significant impairment of quality of life. FPHL diagnosis is mostly clinical. Depending on patient history and clinical evaluation, further diagnostic testing may be useful. The purpose of the paper is to review the current knowledge about epidemiology, pathogenesis, clinical manifestations, and diagnosis of FPHL.

show abstract

Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study

Cited by 11 publications

References 11 publications

Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome

Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome

Contraception and reproductive planning during the COVID-19 pandemic

The Female Pattern Hair Loss: Review of Etiopathogenesis and Diagnosis

Contact Info

Product

Resources

About